Ferric Derisomaltose

Ferric Derisomaltose is a scientifically advanced intravenous iron replacement therapy developed for the effective management of iron deficiency anemia. Unlike conventional iron salts, it is a carbohydrate-based iron (III) complex, offering high stability, safety, and excellent patient tolerability. The formulation is colourless, odourless, and non-hygroscopic, eliminating metallic taste and moisture sensitivity commonly associated with traditional iron preparations. As a leading API manufacturer, WBCIL follows strict cGMP and ISO quality systems, supported by manufacturing expertise since 1962, ensuring consistent potency, purity, and safety across every batch. Key Therapeutic Advantages: • High-dose iron delivery for rapid correction of iron deficiency • Controlled iron release minimizing adverse reactions • Fewer infusions compared to conventional IV iron therapies • Improved patient compliance and clinical outcomes WBCIL Product Highlights: • Patent held by WBCIL on Ferric Derisomaltose • Eminent scientific journals have published studies on WBCIL’s Ferric Derisomaltose • Minimal hypersensitivity reactions reported • Sameness study completed with the innovator product • Compliant with Indian Pharmacopoeia (IP) Applications in Medical Fields: • Iron Deficiency Anemia Treatment • Chronic Kidney Disease • Rapid Iron Replenishment • Postpartum Anemia • Chronic Heart Failure • Inflammatory Bowel Disease